Virulizin
Alternative Names: VirulizinLatest Information Update: 04 Jun 2015
Price :
$50 *
At a glance
- Originator Lorus Therapeutics
- Developer Aptose Biosciences
- Class Antineoplastics
- Mechanism of Action Interleukin 17 stimulants; Tumour necrosis factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Malignant melanoma
- Discontinued Breast cancer; Cervical cancer; Colorectal cancer; Gastric cancer; Kaposi's sarcoma; Lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Uterine cancer
Most Recent Events
- 04 Jun 2015 Discontinued - Phase-III for Pancreatic cancer in USA, Brazil, Canada, Czech Republic, Hungary, Mexico, Poland, Romania, Russia, Spain and Ukraine (IM)
- 02 Sep 2014 Lorus Therapeutics is now called Aptose Biosciences
- 08 Apr 2008 Virulizin® licensed to ZOR Pharmaceuticals in Central, North and South America, Europe and Israel for the treatment of pancreatic cancer and other human therapeutic applications